The Philadelphia (Ph) translocation t(9;22) results in the creation of the BCR-ABL gene, which is now regarded as central to the mechanism that underlies the chronic phase of chronic myelogenous leukemia (CML). From a clinical point of view, BCR-ABL mRNA detection has become the basis for the study of minimal residual disease in CML, particularly when a complete cytogenetic remission is achieved after interferon-alpha (IFN-␣) therapy or allogeneic stem cell transplantation. We have recently demonstrated that it is possible to mobilize normal peripheral blood progenitor cells (PBPC) in higher rates if this procedure is performed during the early chronic phase. In an attempt to monitor the leukemic cell content of PBPC collections, we used quantitative-competitive RT-PCR (QC-RT-PCR). Thirty consecutive Philadelphia (Ph) chromosome positive patients were enrolled in this study. After chemotherapy and G-CSF, 14 patients achieved 100% Ph-negative metaphases, nine patients had р34% and seven patients Ͼ34% leukemic metaphases. A total of 116 collection samples were studied. For each sample, BCR-ABL transcript numbers and BCR-ABL/ABL ratio were evaluated. A highly significant correlation between Ph-positive metaphases and BCR-ABL transcript numbers (r ‫؍‬ 0.84, P Ͻ 0.0001) or BCR-ABL/ABL ratio (r ‫؍‬ 0.86, P Ͻ 0.0001) was found. For patients that underwent the procedure in early chronic phase, Ph-negative collections showed different levels of BCR-ABL expression. BCR-ABL transcript numbers varied from a median of 100/g RNA in the first and second leukaphereses, to 500/g RNA in the third and fourth leukaphereses, and 1500/g RNA in the fifth leukapheresis (P ‫؍‬ 0.002). BCR-ABL/ABL ratio values showed similar kinetics. We have also demonstrated that there is a correlation between low values in BCR-ABL/ABL ratio (р0.01) in the reinfused PBPC and the achievement of cytogenetic remission after autografting ( 2 test, P ‫؍‬ 0.01). In conclusion, this study demonstrates that QC-RT-PCR for BCR-ABL is a reliable and helpful method for monitoring residual leukemic load in mobilized PBPC, particularly in Ph-negative collections. Moreover, QC-RT-PCR allows selection of the best available collections for reinfusion into patients after myeloablative therapy.
Introduction
Chronic myelogenous leukemia (CML) is a stem cell disorder which progresses from an indolent chronic phase to a refractory acute leukemia. In more than 90% of the patients CML is associated with the chromosomal translocation t(9;22), 1 which corresponds, at the molecular level, to the BCR-ABL chimeric gene, 2 essential in CML pathogenesis. 3 At present, allografting is the only possible cure for CML. 4, 5 nately, only one-third of patients can receive this treatment. In younger patients without an HLA-matched donor or in older patients who cannot receive allografting, interferon-alpha (IFN-␣) provides significant cytogenetic remission in about 30-40% of cases. [6] [7] [8] [9] As allografting and IFN-␣ are beneficial only for a fraction of the patients, there is growing interest in autografting. 10 This procedure was employed after the Vancouver group demonstrated that normal but suppressed hematopoietic progenitors are present within the marrow of CML, particularly in the early phases. 11 In the past 9 years, 12 our group demonstrated that an idarubicin-based chemotherapy plus G-CSF is able to mobilize normal stem cells into the blood and that these cells can be used to 'rescue' hematopoiesis after myeloablative therapy. We have also demonstrated that the best results, in terms of Ph-negative collections, were achieved in CML patients mobilized shortly after diagnosis and not pretreated with IFN-␣. 13 In the present study, we monitored the leukemic cells with a quantitative-competitive reverse transcriptase-polymerase chain reaction (QC-RT-PCR) for the BCR-ABL chimeric gene load in peripheral blood progenitor cells (PBPC) collections. This technique, which is presently the most sensitive assay for quantifying leukemic cells in CML, has been previously used to monitor minimal residual disease (MRD) after IFN-␣ therapy 14, 15 and to predict early relapse in allografted patients. 16, 17 
Materials and methods

Patients and samples
Thirty patients with chronic phase CML were studied (Table  1 ). All patients underwent PBPC mobilization and 28 of them transplantation, according to the protocol previously reported. 13 Leukaphereses were started when WBC reached values of у0.8 ×10 9 /l and peripheral CD34 + cells were Ͼ5-10 × 10 6 /l. Leukaphereses were performed on every consecutive days until at least 2 × 10 6 /kg of CD34 + cells were collected. 13 Nineteen patients were mobilized in the first year from diagnosis and did not receive IFN-␣ (group A). Four patients were previously treated with IFN-␣ for less than 12 months (group B) and seven patients received IFN-␣ for more than 12 months (group C).
Quantitative-competitive RT-PCR was available in Genoa in January 1997. Frozen available samples before this date and all samples of cytogenetic remitters after this date were analyzed (Table 1) .
In group A, a median of four leukaphereses was performed (range, 2-6) for a total of 70 collections and 60 (85%) of them were entirely Ph-negative. Fourteen patients had complete cytogenetic response in all collections, while three patients showed complete response at the first collections (two, three and four collections, respectively, in the different patients). Two of the latter patients showed major response in all collections (Table 1) . Three patients were mobilized with the ICE 13 protocol and 16 were mobilized with mini-ICE. 13 In groups B and C, four patients had a major and seven patients a minor response in the collections. Cytogenetic responses to the mobilization procedure are shown in Table  1 . Three to seven collections were performed in these patients, with a median of four, in a total of 46. One patient in group C was mobilized with the ICE protocol, while the other patients were mobilized with mini-ICE. Cytogenetics was available for 38 collections. Thirty-five pre-and post-autologous stem cell transplant (ASCT) samples from the same patients were also included in correlation analysis. In summary, cytogenetic results were available for 143 samples, of which 79 were completely Ph-negative and the other contained a variable amount of Ph-positive metaphases (29 samples with р34%, 16 with 35 to 94% and 19 with more than 95%).
RNA extraction and cDNA synthesis
Cryopreserved cell aliquots from PBPC collection or BM aspirates were thawed, pelletted and lysed in GTC buffer (4 m guanidinium thiocyanate, 0.5% n-laurylsarcosine, 25 mm citrate pH7, 0.1 m ␤-mercaptoethanol). Total RNA was extracted by the acid-guanidinium-phenol-chloroform method. 18 An aliquot of 1-5g RNA was retro-transcribed with 200 U M-MLV reverse-transcriptase (Gibco BRL, San Giuliano Milanese, Italy) for 2 h at 37°C in 20 l, in 1 × RT buffer (provided by the supplier), 10 mm DTT containing 1 g random hexamers and 0.3 U/l RNasin (Boehringer Mannheim, Mannheim, Germany). After enzyme inactivation at 95°C, the reaction mixtures were diluted to 100 l with H 2 O.
Qualitative PCR for p210 BCR-ABL
Qualitative PCR for p210 BCR-ABL was performed in 20 l. For first step PCR, 10 l of the diluted cDNA were amplified in a PCR mix containing 10 mm Tris-HCl, 50 mm KCl, 1.5 mm MgC1 2 , 0.4 mm dNTPs (each), pH 8.3, 0.5 U Taq polymerase and 0.5 mm B-E primer, sequence 5Ј-CGGGAGCAGCAGAA-GAAGTG, and A-E primer, sequence 5Ј-TGTGATTAT-AGCCTAAGACCCGGAG-3Ј. 19 Amplification reactions were performed on the Perkin Elmer 9600 Termal Cycler Apparatus (Roche Molecular Systems, Branchburg, NJ, USA) using a 35 cycle program, with denaturation at 95°C for 30 s, annealing at 62°C for 30 s and extension at 72°C for 30 s. For nested reactions, 1 l of first step PCR was diluted to 20 l in the PCR mix and amplified for 25 cycles as above with B-I and A-I primers, sequences respectively 5Ј-GTGAAACTCCA-GACTGTCCACAGCA-3Ј and 5Ј-TCCACTGGCCACAAAAT-CATACAGT-3Ј. As positive control, PCR for the ABL gene was performed for each cDNA with A2 and A-E primers (sequence for A2 = 5Ј-TTCAGCGGCCAGTAGCATCTGACTT-3Ј). In order to monitor cross contamination, negative control reactions were included at the RNA, cDNA and PCR steps.
Assembling a competitor
To assemble a suitable competitor, a 432-bp b3a2 amplification product, obtained from a chronic phase CML patient by RT-PCR with primers NB1+ and A-E, was digested with AvaII into two fragments of 314-bp (fragment A) and 118-bp (fragment B). A 222-bp fragment derived from AvaII digestion of PBR322 (3504-3726) was purified and ligated separately to fragments A and B (respectively, ligation A and B). Thereafter, one tenth of these reactions was amplified with primers NB1 and PBR-1 for ligation A and with primers A-E and PBR-2 for ligation B. The resulting DNAs were gel-purified, pooled and amplified in an overlapping extension-PCR 20 with primers NB1+ and A-E. The amplified DNA was gel-purified and cloned into pCRII vector (Invitrogen, Leek, Netherlands), originating the pCR-B3ST plasmid (Figure 1) . Sequences of primers NB1+, PBR-1 and PBR-2 were respectively; 5Ј-GAGCGTGCAGAGTGGAGGGAGAACA-3Ј, 5Ј-GGGGGA TCATGTAACTCGCCT-3Ј, 5Ј-ATGGCTTCATTCAGCTCCGGT T-3Ј.
Quantitative PCR for p210 BCR-ABL
For QC-RT-PCR, 5 l cDNA was amplified together with 5 l competitor DNA solution containing from 10 1 to 10 6 competitor molecules, with intermediate points of 0.33-log differences. The equivalence point between the amplification product from the patient and from one of the competitor serial dilutions was determined by computerized video-densitometric analysis of the ethidium bromide stained gel (Fotodyne, Hartland, WI, USA). ABL mRNA was quantitated with the same competitor DNA using A2 and A-E primers. Considering the higher molecular weight of the competitor DNA, conversion factor was 1.5 for b3a2 transcript, 1.8 for b2a2 transcript and 2.1 for ABL transcript. BCR-ABL/ABL ratio was calculated dividing the number of BCR-ABL molecules by the number of ABL molecules. In order to control the effiency of amplification of different DNA fragments, a 432-bp b3a2 amplification product was cloned in pCRII originating the pCR-b3a2 plasmid. Equal numbers of molecules of pCR-b3a2 and pCR-B3ST were amplified as described BCR-ABL and ABL. The ratio of fluorescence between the two bands were in proportion of their size (data not shown).
From December 1997, the pCR-B3ST plasmid was replaced by pNC210/G, kindly provided by Nick Cross (Haematology Department RPMS, Hammersmith Hospital, London, UK) in order to standardize our procedures with the protocols of the European Study Group for CML. This change did not have any effect on the efficiency of our procedure.
In order to study the kinetics of MRD in the Ph-negative collections from the same patient, a relative increment index for BCR-ABL/ABL ratio was obtained for each collection by dividing the BCR-ABL/ABl ratio of a given collection by the lowest BCR-ABL/ABL ratio obtained in all collections from the same patient. By applying this formula, the colletions with the lowest BCR-ABL/ABL ratio had, in every patient, a relative increment = 1.
Statistical analysis
Results were analyzed with the StatView Program (Abacus Concepts, Berkeley, CA, USA). Cytogenetic results were compared BCR-ABL transcripts/g RNA and with BCR-ABL/ABL ratio using the Spearman's rank correlation index. The comparison between collection groups and BCR-ABL transcripts/g RNA, BCR-ABL/ABL ratio or the relative 
Results
Qualitative PCR
A total of 165 samples from 30 CML patients were analyzed by RT-PCR for p210 BCR-ABL transcripts. Contemporaneous cytogenetic analysis was available for 143 samples. In 16 patients, the BCR-ABL gene produced b2a2 transcripts, in 12 patients b3a2 transcripts and in two patients both b2a2 and b3a2 transcripts. 21 
Correlation between QC-RT-PCR and cytogenetics
The number of BCR-ABL transcripts/g RNA varied from 50 to 1 500 000 in the samples examined. The number of ABL transcripts/g RNA ranged from 5000 to 1 500 000 and the BCR-ABL/ABL ratios varied from 0.0001 to 1. We found five samples with BCR-ABL/ABL = 1. A very high transcriptional activity of the BCR-ABL gene could hide the expression of normal ABL gene in these samples. There was a good correlation between BCR-ABL transcripts and contemporaneous percentages of Ph-positive metaphases (n = 143, r = 0.85, P = 0.0001) (Figure 2a ratio and Ph-positive metaphases (r = 0.86, P Ͻ 0.0001) (Figure 2b ). Considering only leukaphereses samples (n = 108), the cytogenetics results correlated strongly with the number of BCR-ABL transcripts (r = 0.081, P Ͻ 0.0001) and with the BCR-ABL/ABL ratio (r = 0.83, P Ͻ 0.0001). Taking into account only the bone marrow pre-and post-ASCT samples (n = 43), the cytogenetics vs QC-RT-PCR correlation indexes were r = 0.66 (P = 0.0002) for number of BCR-ABL transcripts and r = 0.82 (P Ͻ 0.0001) for the BCR-ABL/ABL ratio.
BCR-ABL mRNA variation in Ph-negative PBPC collections
We included in this analysis Ph-negative collections from a total of 17 patients, ie 14 complete responders and three major responders. Quantitative results are shown in Table 2 . The first two groups of collections showed the lowest levels of BCR-ABL mRNA with a median of 100 transcripts/g RNA (range, 50-1000 transcripts/g RNA for the first and 50-3000 transcripts/g RNA for the second collections (Figure 3 ). The number of BCR-ABL transcripts increased in the consecutive collections, with a median 500 transcripts/g RNA in the third and in the fourth leukaphereses (ranges, 100-10 000 and 100-5000, respectively) and 1500 (range, 100-3000) for the fifth (P = 0.002). Similarly, analysis of the BCR-ABL/ABL ratio confirmed a kinetics of MRD increment in successive collections. The BCR-ABL/ABL median values were 0.002, 0.002, 0.006, 0.01 and 0.015 from the first to the fifth group, respectively (P = 0.007) (Figure 3 ). Although Ph-negative collections have been reported more frequently in patients with low Sokal Index, we could not find any statistical correlation between the Sokal index and QC-RT-PCR in PBPC collections, neither BCR-ABL transcripts (P = 0.57), nor BCR-ABL/ABL ratio (P = 0.65).
By examining the relative incredment of BCR-ABL/ABL (see Materials and methods), we found that Ph-negative collections from the same patient may contain different amounts of BCR-ABL RNA, with a relative variation of BCR-ABL/ABL ranging from 1, ie no variation, to 100 (median = 10). A lack of variation of BCR-ABL/ABL ratio was found in only two patients with two collections each. Similar results were found for the number of BCR-ABL transcripts/g RNA (data not shown).
The lowest relative level of BCR-ABL mRNA expression was seen in the first two collections (median = 1), while it clearly increased in the following ones (median 5, 5 and 15 for third, fourth and fifth group, respectively, P = 0.0001).
By evaluating PBPC collections on the basis of the lowest BCR-ABL/ABL ratio and the concomitant presence of progenitors for autografting (2 × 10 6 CD34 + cells/kg), we analyzed whether BCR-ABL quantification could be used to prevent the reinfusion of high numbers of CML cells. We observed that in several patients with Ph-negative collections, an adequate number of CD34 + cells for autografting is contained in the lowest contaminated PBPC (Figure 4 ). These data showed that, by selecting PBPC according to the level of BCR-ABL expression, a lower number of CML cells can be delivered to the patients (Figure 4 ).
BCR-ABL mRNA variation in PBPC collections from pre-treated patients
Quantitative PCR results on the PBPC collections from pretreated patients did not show the same patterns as for group A PBPC, except for the fact that the few Ph-negative collections were generally the first ones ( Figure 5 ). However, these samples showed higher levels of BCR-ABL mRNA compared to the corresponding PBPC from group A patients. Longer duration of the disease together with previous therapies may be responsible for the poorer mobilization results in these patients compared to patients in the early phase of disease.
Clinical results
Twenty-eight patients underwent autografting. Two other patients could not be autografted for refusal (patient A/6) and for voluntary unrelated donor transplant (patient B/1). One patient was autografted but was lost at follow-up thereafter (patient B/2) ( Table 1 ). All autografts were performed with the reinfusion of the PBPC collections analyzed in this study. BCR-ABL/ABL ratio of the reinfused cells is indicated in Table  1 . From January 1997, patients who had multiple Ph-negative collections were autografted with the collections containing the lowest BCR-ABL/ABL ratio and at least 2 ×10 13, 22 The updated cytogenetic status of the patients is also indicated in Table 1 . Clinical results obtained in all groups are discussed in detail elsewere. 13, 22 Interestingly, we found a good correlation between low level of BCR-ABL/ABL ratio in PBPC and cytogenetic remission after autografting ( 2 test, P = 0.01) (Table 3a) . Moreover, PBPC mobilized in patients treated р12 months from diagnosis do better in terms of cytogenetic remissions after autografting ( 2 test, P = 0.008) (Table 3b ).
Discussion
Residual normal hemopoiesis is present at diagnosis in the bone marrow of CML patients, but it declines over time. During chronic phase, the bulk of the leukemic clone can be quite easily destroyed and the original 'normal' population may have a temporary proliferative advantage. 11, [23] [24] [25] [26] This represents the original basis of the mobilization procedure we started in the late 1980s. 12 At that time, we confirmed that it was possible to mobilize normal progenitor cells into the peripheral blood after chemotherapy and G-CSF. 12 Moreover, these progenitors were able to reconstitute the bone marrow of patients after myeloablative therapy, originating a polyclonal hemopoiesis. 27, 28 The best results, in terms of cytogenetic response and number of progenitors collected, were obtained in patients treated during early chronic phase. 13 These results have been recently confirmed by other groups. [29] [30] [31] In an attempt to follow-up the response to therapy as well as to improve the quality of the reinfused progenitor cells, we monitored the leukemic contamination of the PBPC collections by QC-RT-PCR for BCR-ABL. This technique, originally developed by Lion 14, 16 and Cross, 15,17 proved a reliable and sensitive way to analyze the kinetics of MRD in CML patients treated with IFN-␣ or allografting. A BCR-ABL/ABL ratio value of more than 0.02% has been recently proposed by J Goldman (personal communication) as the first evidence of relapse in allotransplanted patients. In patients treated with IFN-␣, the cytogenetics correlated with both BCR-ABL transcript number and BCR-ABL/ABL ratio. 15 The first objective of this study was to demonstrate that QC-RT-PCR is a reliable system to monitor MRD in the collections. In order to produce a suitable competitor DNA, we set up a fast PCR-based procedure to introduce a foreign fragment of DNA in a patient-derived amplification product. This system is potentially applicable for producing DNA constructs specific for other competitive assays. We found that the levels of BCR-ABL expression, either expressed as BCR-ABL transcript numbers or as BCR-ABL/ABL ratio, correlated with the cytogenetic response. Interestingly, the BCR-ABL/ABL ratio correlated with the percentage of Ph-positive cells to the same extent as the absolute BCR-ABL transcript number, confirming what had been seen in patients treated with IFN-␣. 15 In this system, quantification of the message from the internal standard ABL gene normalizes for the variability in the quality of biologic samples. This is crucial to compare results from dif-ferent laboratories. PCR-negative leukaphereses from CML patients have been reported; 30 however, the threshold sensitivity of an RT-PCR assay may vary among different laboratories and also among different samples from the same experiment. The assay sensitivity must be controlled in terms of total ABL mRNA competitive quantification. Therefore, QC-RT-PCR is a powerful tool for monitoring the leukemic load of PBPC and, by implication, the clinical response to mobilization therapy. Furthermore, this assay is the system of choice in Ph-negative samples. The second objective of this study was to evaluate the MRD content of Ph-negative collections mobilized during the early phase of the disease. These samples contained different levels of BCR-ABL transcripts (range, 50 to 10 000/g RNA). This variability was also shown in different phereses from the same patient. In some cases, a 2-log difference was observed between different collections in the same patient. Each patient showed unique kinetics of BCR-ABL expression, but a constant finding was that the first or the second phereses contained the lowest level of leukemic cells. Indeed, a steady increment in BCR-ABL expression was found in the subsequent collections. This is in line with experimental and clinical data from the literature and from ourselves: 13 hematopoietic normal progenitors are mobilized earlier than the leukemic progenitors.
Finally, the accurate quantification of the MRD allows to select the PBPC with the lowest leukemic load for autografting. Our preliminary data show that the cells collected in the early phase of recovery after aplasia induced by chemotherapy and G-CSF and selected according to the lowest content of disease, are able to engraft and to maintain hematopoiesis indefinitely. The preliminary analysis of the patients studied in this report suggests that the reduction of the CML cells in the graft may affect favorably the clinical response to autografting in this disease.
